Compare · CV vs INMD
CV vs INMD
Side-by-side comparison of CapsoVision Inc. (CV) and InMode Ltd. (INMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and INMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD is the larger of the two at $765.9M, about 2.3x CV ($335.9M).
- Both names hit the wire about 2 times in the past 4 weeks.
- INMD has more recent analyst coverage (20 ratings vs 3 for CV).
- Company
- CapsoVision Inc.
- InMode Ltd.
- Price
- -
- -
- Market cap
- $335.9M
- $765.9M
- 1M return
- -4.76%
- -
- 1Y return
- +31.35%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2019
- News (4w)
- 2
- 2
- Recent ratings
- 3
- 20
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest CV
- Amendment: SEC Form SCHEDULE 13G/A filed by CapsoVision Inc.
- CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026
- CapsoVision to Present at the 20th Annual LD Micro Main Event
- SEC Form 8-K filed by CapsoVision Inc.
- CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
- Large owner Harari Eliyahou Et Al bought $9,999,999 worth of shares (1,757,469 units at $5.69) (SEC Form 4)
- Amendment: Large owner Shen Ching Hang disposed of 3,991,606 shares and acquired 3,991,606 shares, closing all direct ownership in the company (SEC Form 4)
- Amendment: Large owner Shen Ching Hang bought $4,999,996 worth of shares (878,734 units at $5.69) (SEC Form 4)
- Large owner Shen Ching Hang bought $4,999,996 worth of shares (878,734 units at $5.69) (SEC Form 4)
- SEC Form 8-K filed by CapsoVision Inc.
Latest INMD
- SEC Form 6-K filed by InMode Ltd.
- Steel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash Offer
- InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- SEC Form 6-K filed by InMode Ltd.
- InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
- SEC Form 6-K filed by InMode Ltd.
- Chief Financial Officer Itzkovich Moshe was granted 14,000 units of Ordinary Shares, increasing direct ownership by 57% to 38,430 units (SEC Form 4)
- SEC Form 6-K filed by InMode Ltd.
- InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One